Abstract 1133
Background
Immune checkpoint inhibitors are an important therapy. However, their essence is nonspecific and efficiency of single usage is not satisfactory. The mutant neoantigen specific T (Nas-T) cell, as an adoptive cell treatment, is a specific immunotherapy for each individual. Our previous research has proved that the combined immunotherapy of mutant Nas-T cell and PD1 antibody is more effective than PD1 alone in prolonging PFS (World Conference on Lung Cancer 2018). We aim to evaluate the characteristics of the immune repertoire (IR) as a predictive biomarker for immunotherapy and to construct personalized and specific TCR-T.
Methods
14 patients with advanced solid tumors who failed after multiline treatments were recruited. They were divided into durable clinical benefit (complete response, partial response or stable disease for more than 3 months) and non-durable clinical benefit (DCB and NCB) based on PFS. Peripheral blood was collected at baseline and each cycle. IR-seq of the CDR3 regions of human TCRβ chains was used to interrogate the TCRs frequency. We used single neoantigen to stimulate the infused T cells and performed RNAseq for the sorted CD137(+) cells to obtain the full-length TCR α and β chain. Lastly, we constructed TCR-T cells via transfecting the TCR α/β pair into the T cells of patients and co-cultured with neoantigen to analyze the functionality of TCRs.
Results
After neoantigen pulsing, the clonality of infused T cells pool significantly increased (P = 0.0001), suggesting some tumor-specific T-cells were expanded and enriched after neoantigen pulsing. Compared to baseline, T-cell repertoire of NCB and DCB after 1st cycle displayed significant changes: Shannon 1.19 vs 0.97 (P = 0.002); clonality 0.68 vs 1.19 (P = 0.001). Elevated clonality may indicate expanded tumor-specific T-cells which could recognize mutant neoantigen specifically. Besides, based on the in vitro TCR-T experiments, the constructed TCR-T cells can specifically recognize the mutant neoantigen and lyse the target cells expressing the corresponding neoantigen.Table:
1228P
Neoantigen Sequence | HLA-I typing | TCR Vα | TCR Vβ | |||
---|---|---|---|---|---|---|
Gene name | Sequence* | All V Hits With Score# | Clonal Sequence# | All V Hits With Score# | Clonal Sequence# | |
MTAP/SPINK1 Fused Gene | VLLPRHMKV | A0201 | TRAV35 (574.6) | TGTGCTGGGTATGGCTCTAGCAA CACAGGCAAACTAATCTTT | TRBV19 (646.8) | TGTGCCAGTCGGACAGGGGGA TCACCCCTCCACTTT |
FER | NYVSNVSKF | A2301 | TRAV29DV5 (667.6) | TGTGCAGCTTCAACTGGGGCAAA CAACCTCTTCTTT | TRBV7-2 (626.7) | TGTGCCAGCACCTCTGCCCCC TCCTACGAGCAGTACTTC |
SPINK1 | FLLSALALL | B4403 | TRAV20 (589.1) | TGTGCTGTTCCCCTGGGAACAGG CTTTCAGAAACTTGTATTT (response to neoantigen) | TRBV21-1 (557.8) | TGTGCCAGCAGCAAAGACCCT AGCGGGAATCAAGAGACCCAGTACTTC |
CLCN6 | ALIGAAASL | B6701 | TRAV19 (612.4) | TGTGCTCTTCTGAATTATGGTGGTGC TACAAACAAGCTCATCTTT | TRBV6-5 (675.4) | TGTGCCAGCAGTGGGACAGCCAATGA GCAGTTCTTC (response to neoantigen) |
MTAP | AESFMFRTW | C0401 | TRAV38-2DV8 (658.4) | TGTGCTTATTGGGAGCTTGTCTCTGGGG CTGGGAGTTACCAACTCACTTTC | TRBV5-1 (637.6) | TGCGCCAGCAGCTTGACTAGCGGGGGG TTCTACGAGCAGTACTTC |
TAP1 | RLSLFLALV | C0702 | TRAV16 (622.2) | TGTGCTCCCTGGGCCCTAGGAGGAGG TGCTGACGGACTCACCTTT | TRBV30 (403.4) | TGTGCCTGGAGTGTAACAGGGGGC AAAGCAGATACGCAGTATTTT |
MAN2C1 | FLQGRNFFL |
Conclusions
The mutant Nas-T cell is a personalized immunotherapy. IR is a potential predictive biomarker.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shunchang Jiao.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract
5529 - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Presenter: Robert Tauber
Session: Poster Display session 3
Resources:
Abstract